Subscribe to Biotech Blueprint for free at ⁠biotechblueprint.com⁠. About this episode: mRNA’s next chapter isn’t just flu and COVID. We break down why latent viruses (CMV, EBV, HSV) persist, why T cells matter, and how multi-antigen mRNA vaccines aim to control reactivation. We also cover Moderna’s CMV Phase 3 (mRNA-1647) as a platform stress test and the rise of personalized neoantigen cancer vaccines (V940) that cut melanoma recurrence vs Keytruda alone in Phase 2b and are now in Phase 3. What success here would mean for public health, operations, and the mRNA platform.

Ver todos los episodios